Candel Therapeutics, Inc. (CADL): Price and Financial Metrics

Candel Therapeutics, Inc. (CADL): $5.19

0.09 (-1.70%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add CADL to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#200 of 329

in industry

CADL Price/Volume Stats

Current price $5.19 52-week high $14.30
Prev. close $5.28 52-week low $0.75
Day low $5.18 Volume 124,600
Day high $5.44 Avg. volume 1,875,848
50-day MA $6.34 Dividend yield N/A
200-day MA $5.46 Market Cap 166.52M

CADL Stock Price Chart Interactive Chart >


Candel Therapeutics, Inc. (CADL) Company Bio


Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of cancer immunotherapy drugs. The company offers Gene Mediated Cytotoxic Immunotherapy technology-based drugs that are designed to work with radiation, chemotherapy, and surgery to eradicate residual tumor cells that could lead to recurrence or metastases. Its product candidates include CAN-2409, an off-the-shelf adenovirus product candidate, for the treatment of localized, primary prostate cancer and therapy for pancreatic cancer; and CAN-3110, its HSV product candidate, has been engineered for enhanced specificity and tumor cell killing, while minimizing toxicity on healthy tissue and indicated for the treatment of recurrent high-grade glioma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was founded in 1999 and is based in Needham, Massachusetts.


CADL Latest News Stream


Event/Time News Detail
Loading, please wait...

CADL Latest Social Stream


Loading social stream, please wait...

View Full CADL Social Stream

CADL Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2023 N/A
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!